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A survey was carried out to determine the prevalence 
and appropriateness of antimicrobial therapy (AMT) in 
the Netherlands and to identify determinants for inap-
propriate AMT. Prevalence surveys of patients hospi-
talised in the Netherlands were performed three times 
in 2008 and 2009. Patients’ demographic, infection-
related and AMT-related data were collected from 
hospital wards. A total of 19 hospitals participated, 
consisting of a mix of university, teaching and general 
hospitals, which were distributed evenly across the 
country. The appropriateness of AMT was assessed 
using a standardised algorithm based on local AMT 
prescription guidelines. A total of 7,853 patients were 
included, of which 2,327 (29.6%) patients were on AMT 
(range: 20.8–39.5%). In 372 patients (16% of patients 
on AMT), treatment was considered inappropriate. In 
265 (11.4%) patients on AMT, appropriateness of treat-
ment was not judged because of insufficient informa-
tion. The percentage of patients without a judgment 
varied considerably between the participating hos-
pitals (range: 1.3–36.2%). Appropriate AMT use was 
significantly associated with a patient being in an 
intensive care unit, having a central venous catheter 
and being given beta-lactamase-sensitive penicillins. 
The use of fluoroquinolones was significantly associ-
ated with more frequent inappropriate use. There was 
considerable and significant variation between the 
participating hospitals in the amount of antimicrobi-
als prescribed and the appropriateness of their use. To 
improve the completeness and reliability of such sur-
veys, there is a need for intensive training of observ-
ers and medical staff in recording information.
Introduction
Point prevalence surveys are useful ways of inves-
tigating healthcare-related events, including anti-
microbial use. The first report on antimicrobial use 
measured in prevalence surveys was published in 
1983 [1]. More recently a European project – the 
European Surveillance of Antimicrobial Consumption 
(ESAC) – has standardised a method to determine the 
prevalence of antimicrobial therapy (AMT) in hospitals 
[2]. In a previous study, performed in a teaching hos-
pital in the Netherlands, we showed that besides the 
prevalence of AMT, the appropriateness of AMT for indi-
vidual patients could also be determined, basing the 
judgement on local antibiotic prescription guidelines 
[3]. This enables researchers to quantify the number 
of patients who are treated even when treatment is 
not indicated or who are treated with a drug that is 
not the preferred choice. In addition, it was possible 
to identify determinants of inappropriate use of AMT 
[3]. The objective of the current study was to determine 
whether prevalence studies could be used in other hos-
pitals as well and whether they could also be used as a 
tool for benchmarking. 
The study was coordinated by the PREZIES (Prevention 
of Nosocomial Infections by Surveillance) network – 
a collaboration between participating hospitals, the 
Dutch Institute for Healthcare Improvement (CBO) 
and the National Institute for Public Health and the 
Environment (Rijksinstituut voor Volksgezondheid en 
Milieu, RIVM), RIVM). 
Methods 
Prevalence surveys
Hospitals were recruited from PREZIES. Those that had 
already participated in prevalence surveys for nosoco-
mial infections were invited to add AMT use to this sur-
vey. Participation was on a voluntary basis.
Three prevalence surveys of hospitalised patients were 
performed in spring 2008, autumn 2008 and spring 
2009. All patients that were present in the hospital at 
00:01 on the day of the survey were included. Patients 
in day care (including haemodialysis patients) and psy-
chiatric wards were excluded. Data from the hospital 
wards were collected by infection control practitioners. 
A standardised case record form, to document patients’ 
demographic, infection-related and AMT-related data, 
was used. The infection control practitioners received 
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training during workshops on how to collect the data 
and how to judge the appropriateness of AMT. The 
following demographic variables were recorded: age, 
sex, medical speciality, type of ward and presence of 
infection on admission. Nosocomial infections were 
recorded using the definitions from the United States 
Centers for Disease Control and Prevention (CDC) and 
patients had to be symptomatic or still being treated 
on the day of the survey [4,5]. Furthermore, the use of 
antimicrobial agents and dosage were noted. If more 
than one antimicrobial was prescribed for one patient, 
all antibiomicrobials, up to a maximum of three, were 
registered. Antifungal and antiviral therapy as well 
as medication for tuberculosis were excluded from 
the study. The main reasons were that not all local 
guidelines had specific recommendations for these 
agents and susceptibility of pathogens to these agents 
was not always determined by the local microbiology 
laboratories.
Appropriateness of antimicrobial therapy
The appropriateness of AMT was determined using a 
standardised method developed by Gyssens et al. [6], 
using the following classifications: correct decision, 
incorrect decision, incorrect choice or insufficient data. 
This classification system obviously only takes into 
account patients that are on AMT. However, using our 
approach it is possible to examine the appropriateness 
of not prescribing AMT also, as described in our previ-
ous study [3]. A correct decision was deemed appro-
priate; incorrect decision and incorrect choice were 
considered inappropriate (the evaluation criteria are 
summarised in Table 1). 
The appropriateness of AMT was judged according to 
the local AMT prescription guidelines present in all 
participating hospitals. These local guidelines are 
based on the national policy developed by the Dutch 
Working Party on Antibiotic Policy (Stichting Werkgroep 
Antibiotica Beleid, SWAB) [7,8]. The infection control 
practitioners assessed the appropriateness of AMT 
initially: if they could not decide, a consultant micro-
biologist or infectious disease physician made the final 
judgment. The consultant microbiologist or infectious 
disease physician also judged all patients in inten-
sive care units, all patients who received AMT without 
having an active infection (according to the survey), 
all patients who did not receive AMT and did have an 
active infection and all patients who received AMT that 
was not according to the local AMT guidelines.
If all the antimicrobial agents that a patient received 
were considered correct, the treatment was considered 
appropriate. If one or more of the antimicrobial agents 
was considered incorrect, the treatment was consid-
ered inappropriate. If it was not possible to decide 
whether use of a particular antimicrobial agent was 
correct due to incomplete information, treatment was 
recorded as insufficient information. We did not assess 
the reproducibility of the judgments.
Data analysis, quality control 
and statistical analysis
Privacy of patients is ensured by decoding all data, as 
required by the privacy regulations in the Netherlands. 
Data were entered in the PREZIES database or a hos-
pital-owned database and subsequently coded and 
transferred to PREZIES.
Data were analysed using SPSS version 17.0. Treatment 
for which there was insufficient information was 
recorded as a missing value. Categorical variables 
were analysed by Fisher’s exact test or chi-square test 
where appropriate: continuous variables were analysed 
using a t-test or Mann–Whitney U test where appropri-
ate. Binary logistic regression analysis was performed: 
all variables with a p value less than 0.1 in univariate 
analyses were entered into the multivariate model. 
Statistical significance was accepted when the chance 
for coincidence was less than 5%. Finally, a sensitiv-
ity analysis was performed. In this, the univariate and 
multivariate analyses were repeated: once categorising 
AMT use as appropriate for all patients for whom AMT 
use could not be judged and once categorising it as 
inappropriate.
Results
A total of 7,853 patients were included, from 19 hospi-
tals. They were a mix of university, teaching and gen-
eral hospitals, which were distributed evenly across 
the country. Of these, 13 participated in one of the 
three surveys, five participated in two surveys and one 
participated in all three. A mean of 302 patients were 
included per hospital per prevalence survey (range: 
103–552; standard deviation: 149).
Table 1
Evaluation criteria for appropriateness of antimicrobial 
therapy, the Netherlands, 2008–2009
Categories and criteria
1. Correct decision (appropriate use)
1.1 No AMT and no infection and no AMT needed
1.2 No AMT and infection and no AMT needed
1.3 AMT and infection and appropriate choice and appropriate 
use
2. Incorrect decision (inappropriate use) 
2.1 No AMT and infection and AMT needed
2.2 AMT and no infection and no prophylaxis and no AMT needed
2.3 AMT and no infection and prophylaxis and no AMT needed
3. Incorrect choice (inappropriate use)
3.1 Divergence from guidelines
4. Missing data (insufficient information)
4.1 No AMT and not enough diagnostic information about 
infection
4.2 Infection and not enough diagnostic information if AMT is 
needed
4.3 AMT and not enough diagnostic information about infection
4.4 Infection and not enough information about AMT
AMT: antimicrobial therapy.
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Patient characteristics and 
nosocomial infections
Overall 3,784 (48.2%) patients were male, and the 
mean age was 62 years (median: 67 years). On the 
day of the survey 426 patients (5.4%) had at least one 
active nosocomial infection.
Antimicrobial therapy
A total of 2,327 patients (29.6%) were on AMT (range: 
20.8–39.5%). The mean prevalence of AMT per partici-
pating hospital is shown in Figure 1. 
Of the 2,327 patients on AMT, 433 (18.6%) were treated 
with two antimicrobials, and 58 (2.5%) were treated 
with three or more. In total 2,876 courses of antimicro-
bial agents were administered, of which 1,709 (59.4%) 
were given intravenously (range: 42.2–75.9%).
The first antimicrobial agent was considered appropri-
ate in 1,690 (72.6%) patients. In 149 (6.4%) patients the 
first antimicrobial agent was considered not justified 
Figure 1
Mean prevalence of antimicrobial therapy per participating hospital, the Netherlands, 2008–2009
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Figure 2
Inappropriate antimicrobial therapy and proportion of patients without antimicrobial therapy judgmenta, by participating 
hospital, the Netherlands, 2008–2009
The hospitals are shown in order of increasing proportion of inappropriate use.
a Due to missing information.
b The numbering of hospitals is identical to the hospital numbers in Figure 1.
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and therefore inappropriate. In 223 (9.6%) patients 
AMT was justified, but the choice of the agent was not 
according to the guidelines. In 265 (11.4%) patients no 
decision was made due to insufficient information. The 
second antimicrobial agent was considered appropri-
ate in 384 patients (78.2% of the 491 patients treated 
with more than one antimicrobial agent), not justi-
fied in 26 (5.3%) and justified but an incorrect choice 
in 39 (7.9%) patients. In 42 (8.6%) patients no choice 
was made due to insufficient information. The third 
antimicrobial was considered appropriate in 50 of the 
58 patients treated with at least three antimicrobial 
Table 2
Use of antimicrobial agents in participating hospitals, the Netherlands, 2008–2009 
Antimicrobial agent 
First antibiotic Second antibiotic Third antibiotic Total
n % n % n % n %
beta-lactamase-sensitive penicillins 58 2.5 12 2.4 1 1.7 71 2.5
beta-lacatamase-resistant penicillins 150 6.4 17 3.5 1 1.7 168 5.8
Carbapenems 44 1.9 5 1.0 2 3.4 51 1.8
Co-amoxicillin-clavulanic acid 715 30.7 42 8.6     757 26.3
First-generation cephalosporins 124 5.3 2 0.4 1 1.7 127 4.4
Second-generation cephalosporins 147 6.3 35 7.1 2 3.4 184 6.4
Third- and fourth-generation cephalosporins 177 7.6 30 6.1 4 6.9 211 7.3
Co-piperacillin-tazobactam 63 2.7 7 1.4 3 5.2 73 2.5
Sulfonamides and trimethoprim 107 4.6 15 3.1 3 5.2 125 4.3
Fluoroquinolones 303 13.0 93 18.8 8 13.8 404 14.0
Glycopeptides 37 1,6 16 3,3 2 3,4 55 1,9
Imidazole derivates 55 2,4 68 13,9 4 6,9 127 4,4
Lincosamides and macrolides 84 3,6 39 8,0 10 17,2 133 4,6
Broad-spectrum penicillin 128 5,5 34 6,9 2 3,4 164 5,7
Aminoglycosides 30 1,3 40 8,2 8 13,8 78 2,7
Tetracyclines 42 1,8 6 1,2 1 1,7 49 1,7
Other antimicrobials 63 2,7 30 6,1 6 10,3 99 3,4
Total 2,327  81 491 17 58 2 2,876a 100 
a Total number of courses of antimicrobial agents administered that were recorded on the survey days.
Figure 3
Relative risk for inappropriate use of antimicrobial therapy by group of antimicrobial agenta, the Netherlands, 2008–2009
Vertical bars represent the 95% confidence intervals.
a Co-amoxycillin-clavulanic acid as reference.
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agents, not justified in two and justified but an incor-
rect choice in two patients. Four were not judged due to 
insufficient information.
Judgment of the appropriateness of AMT per patient 
showed that 372 patients (16% of the patients on AMT; 
4.7% of the total population) were treated inappropri-
ately. Figure 2 shows the variations in the proportion 
of AMT considered inappropriate in the different hospi-
tals (range: 5.0–32.4%). 
For 265 patients (11.4%) on AMT it was not possible to 
judge appropriateness because of insufficient informa-
tion. Figure 2 shows the variations in the proportion 
of patients on AMT who could not be judged in the par-
ticipating hospitals (range: 1.3–36.2%). 
Of the patients who did not receive AMT (n=5,526), 945 
were not judged for the appropriateness of the decision 
not to treat. This was mainly due to four hospitals that 
did not judge patients who were not receiving AMT. Of 
the 4,581 patients not receiving AMT who were judged, 
the decision not to use AMT was considered appropri-
ate for 4,497 (98.2%) patients. For 22 patients (0.5% of 
those not on AMT who were judged), patients did not 
receive AMT, although this was indicated. For 62 (1.4%) 
patients not on AMT it was not possible to assess the 
appropriateness because of insufficient information.
Figure 5
Relative risk for inappropriate use of antimicrobial therapya, the Netherlands, 2008–2009
Vertical bars represent the 95% confidence intervals.
a All determinants are dichotomous variables, which are compared to their counterpart.
b Extended-spectrum beta-lactamase-producing Gram-negative rods.
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Relative risk for inappropriate use of antimicrobial therapy by medical specialtya, the Netherlands, 2008–2009
Vertical bars represent the 95% confidence intervals.
a Internal medicine as reference.
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Table 2 shows the distribution of the use of various 
antimicrobials. Co-amoxicillin-clavulanic acid was 
most commonly used, second were the fluoroquinolo-
nes and the third were the third- and fourth-generation 
cephalosporins.
Determinants of inappropriate 
use of antimicrobial therapy
In the univariate analysis, use of fluoroquinolones 
was significantly associated with more frequent inap-
propriate use of AMT (relative risk: 1.4). The use of 
beta-lactamase-sensitive penicillins was significantly 
associated with more frequent appropriate use of AMT 
(relative risk: 0.3) (Figure 3). 
Considering the use of AMT in the different medical 
specialties, urology (p=0.002) proved to be signifi-
cantly associated with more frequent inappropriate 
use (Figure 4). None of the specialties was significantly 
associated with more frequent appropriate use. 
Figure 5 shows that the presence of a suprapubic cath-
eter was significantly associated with more frequent 
inappropriate use (relative risk: 1.9). The following 
factors were associated with more frequent appropri-
ate use of AMT: having a central venous catheter, a 
peripheral vascular catheter or an arterial catheter, the 
presence of ESBL (extended-spectrum beta-lactamase-
producing bacteria, being admitted to an intensive care 
unit, being in isolation precautions and having a noso-
comial infection. 
In multivariate analyses, taking the effects of all the 
above-mentioned variables into account, we found that 
the hospitals themselves were important determinants 
associated with appropriate or inappropriate use of 
AMT (Table 3). Furthermore, increasing age (p=0.024), 
being in an intensive care unit (p=0.002), having a cen-
tral venous catheter (p=0.12), peripheral vascular cath-
eter (p=0.005) and nosocomial infection (p=0.049) and 
use of beta-lactamase-sensitive penicillins (p=0.017) 
were significantly associated with appropriate use in 
multivariate analyses. The presence of a suprapubi-
cal catheter (p=0.017) or the use of fluoroquinolones 
(p<0.001) were significantly associated with inappro-
priate use of AMT. No colinearity was found between 
the variables in the multivariate model.
Discussion and conclusions
The mean prevalence of AMT in this study was 29.6% 
(range: 20.8–29.5%). The most recent study that 
can be used for comparison is from the European 
Surveillance of Antimicrobial Consumption (ESAC) 
which found a similar prevalence of 30% (range: 19 
–59%) in 20 European hospitals in 2006 [2]. Other 
prevalence studies in hospitals in the United Kingdom 
and Turkey also showed similar rates of antimicrobial 
use [9-11]. Although the overall prevalence in our study 
is comparable to that of other large surveys, there were 
large variations between the participating hospitals. 
This range of appropriate AMT use can be explained 
by differences in the patient populations and by differ-
ences in prescription policies between hospitals and 
between individual prescribers. 
Of all patients on AMT in this study, the use was con-
sidered inappropriate in 372 (16%; range: 1.9–27.7%). 
The patients concerned comprised 4.7% of the total 
number of patients, which may seem relatively unim-
portant. However, this means that annually approxi-
mately 10,000 days of unjustified AMT are given in a 
hospital with 200,000 patient days a year. Treating 
patients with AMT when such treatment is not indicated 
is known to be associated with higher costs, more side 
effects and more antimicrobial resistance [12,13].
Our study showed that the proportion of patients for 
whom AMT was judged to be inappropriate varied 
between hospitals. AMT use could not be judged for 
265 patients due to insufficient information. Deciding 
on the appropriateness of AMT use is often not easy. 
However, the difference between the hospitals is 
remarkable. The hospitals with the lowest proportion 
of cases that could not be judged were hospitals with 
previous experience with this kind of survey. Possibly 
these kinds of judgments require more extensive train-
ing. During a session that was organised with the 
infection control practitioners and consultant micro-
biologists to discuss the findings, it was thought that 
more training and discussion of difficult cases in the 
study group would probably result in a reduction of the 
number of cases that could not be judged. 
Our study showed that the participating hospital is 
a determinant itself and had a great influence in the 
analyses of determinants associated with inappropri-
ate or appropriate AMT use. We were unable to iden-
tify specific characteristics of the hospitals that were 
responsible for more frequent inappropriate use. 
Nevertheless, use of fluoroquinolones proved to be 
a significant risk factor for inappropriate use of AMT. 
Fluorouinolones were the second most frequently used 
antimicrobials. The ESAC reported that use of fluoro-
quinolones increased most rapidly of all groups of anti-
microbial agents, with a rise of 15% or more from 2000 
to 2005 in almost half of all participating countries [14]. 
At the same time antimicrobial resistance against the 
fluoroquinolones increased from 5% (in 2001) to 14% 
(in 2008) in Escherichia coli and from 4% (in 2005) to 
8% (in 2008) in Klebsiella pneumoniae [15]. This high-
lights the importance of undertaking targeted interven-
tions to reduce inappropriate use of fluoroquinolones. 
Data from prevalence surveys such as those described 
here provide support for such action.
Other determinants associated with a more appropri-
ate use of AMT were variables associated with the 
clinical complexity of the patients (e.g. being admitted 
to an intensive care unit and having a central venous 
catheter). In the Netherlands, a microbiologist or infec-
tious disease physician is almost always consulted in 
the assessment of these complicated cases. However, 
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the largest group of patients being treated with antibi-
otics comprises relatively uncomplicated cases: most 
of these are not monitored by the microbiologist or 
infectious disease physician. A prevalence survey does 
include this group of patients and delivers information 
on the appropriateness of use. In our experience, it is 
this group in which a substantial improvement of the 
quality of antibiotic prescription can be achieved.
The fact that the treatment or lack of treatment of some 
patients could not be judged may have affected the 
outcome of our study. However, a  sensitivity analysis 
showed that this did not affect the conclusions about 
the appropriateness of AMT use in the participating 
hospitals. We did not collect information on what fac-
tors in the hospitals with higher inappropriate use may 
have contributed to this. Further studies are warranted, 
since they may offer clues for further improvement. 
In this study we identified those patients who inadvert-
ently did not receive AMT (22 patients, 0.3% of total 
study population). There was no further analysis of the 
22 patients. In an earlier single-centre study, we found 
a similar fraction of such patients (25 patients, 0.6% of 
total study population); further investigation showed 
that those patients were not adversely affected at dis-
charge [3].
The extent of intravenous administration of anti-
microbials (59.4%) suggests that there is room for 
improvement. Intervention studies performed in the 
Netherlands showed that intravenous administration 
can be reduced relatively easily by targeted interven-
tions [16,17]. A switch to oral therapy often results in 
a shorter hospital admission. In our study, the appro-
priateness of the route of administration was not 
assessed
In conclusion, we have demonstrated that it is possible 
to collect prevalence data on use of AMT at a national 
level. Individual hospital data can be very helpful in 
initiating targeted interventions to improve AMT use 
[17]. However, in order to produce more reliable results 
of such surveys, the number of patients for whom the 
appropriateness of AMT use could not be judged has 
to be reduced. Therefore training of infection control 
practitioners and consultant microbiologists has to be 
intensified and medical staff need to be trained in how 
to record information, in order to get an unambiguous 
assessment of use of AMT.
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